Drug Type Bispecific antibody |
Synonyms MAS 825, MAS825 |
Target |
Mechanism IL-18 inhibitors(Interleukin 18 inhibitors), IL-1β inhibitors(Interleukin-1 beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coronary Disease | Phase 2 | US | 15 Feb 2024 | |
Coronary Disease | Phase 2 | CA | 15 Feb 2024 | |
Coronary Disease | Phase 2 | DE | 15 Feb 2024 | |
Hidradenitis Suppurativa | Phase 2 | CH | 09 Feb 2022 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | US | 18 Dec 2020 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | JP | 18 Dec 2020 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | CA | 18 Dec 2020 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | CZ | 18 Dec 2020 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | FR | 18 Dec 2020 | |
Autoinflammation With Infantile Enterocolitis | Phase 2 | IT | 18 Dec 2020 |
Phase 2 | Respiratory Insufficiency C-reactive protein (CRP) | SARS-CoV-2 presence | inflammatory markers | 138 | yuwhgilblj(wzhhjdtwqx) = None of the adverse events (AEs) or serious AEs were treatment-related djnevzfoik (ezmdsbluwv ) View more | Positive | 13 Oct 2023 | ||
Placebo | |||||||
Phase 2 | 140 | Standard of Care (SoC)+MAS825 (MAS825 + SoC) | bisrxxwwjz(vbdclksoce) = abeuujvwwv orfjlxxdts (lpceaycyxd, zxfqdqnzje - dwblkufyjd) View more | - | 20 Apr 2022 | ||
Placebo (Placebo + SoC) | bisrxxwwjz(vbdclksoce) = zrxsuarect orfjlxxdts (lpceaycyxd, hejtbpsoiz - uegsewzmbo) View more |